Assertio Holdings Reports 62.5% Revenue Decline and $18.9 Million Net Loss in Q1 2026

Assertio Holdings, Inc. reported a significant decline in financial performance for the first quarter of 2026, as detailed in its latest 10-Q filing. The company generated total revenues of $9.9 million, a decrease of 62.5% from $26.5 million in the same period last year. This decline was primarily driven by a sharp drop in product sales, which fell to $8.9 million from $26.0 million, largely due to lower sales volumes of its lead product, ROLVEDON, which saw net sales of only $0.5 million compared to $13.1 million in the prior year. The company attributed this decrease to strategic inventory purchases made by distributors in late 2025, which resulted in reduced sales in early 2026.

In terms of profitability, Assertio reported a net loss of $18.9 million, or $2.93 per share, compared to a net loss of $13.5 million, or $2.12 per share, in the first quarter of 2025. The increase in net loss was influenced by higher operating expenses, which totaled $28.4 million, down from $39.7 million a year earlier, but still reflected significant costs associated with selling, general, and administrative expenses, as well as amortization of intangible assets. The company’s cash and cash equivalents increased to $33.7 million from $10.2 million at the end of 2025, bolstered by improved cash flow from operations.

Strategically, Assertio has undergone significant changes, including the completion of an asset sale to Cosette Pharmaceuticals on April 8, 2026, for $35 million, which included several product lines such as INDOCIN and SPRIX. This divestiture is part of a broader strategy to focus on ROLVEDON, which is now the company's sole marketed product. Additionally, Assertio entered into a merger agreement with Garda Therapeutics, which was amended to increase the acquisition price to $21.80 per share, reflecting a shift in the company’s strategic direction.

Operationally, the company has seen fluctuations in its customer base and product engagement metrics. The number of shares outstanding increased slightly to 6,462,180 as of May 6, 2026, following a reverse stock split in December 2025. The company’s management indicated that sales of ROLVEDON are expected to normalize in the second quarter of 2026, following the completion of integration efforts and the resumption of regular sales volumes. However, the outlook remains cautious, with management highlighting the need to navigate ongoing market conditions and the competitive landscape, particularly with the impending launch of biosimilars.

Looking ahead, Assertio's management expressed optimism about the potential for ROLVEDON, contingent on successful marketing and distribution strategies. However, the company also acknowledged the risks associated with the merger and asset sale, including potential impacts on operational focus and financial stability. The completion of the merger with Garda Therapeutics and the successful execution of the asset sale will be critical in shaping Assertio's future financial health and operational strategy.